MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy

MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy

Aim: MET exon 14 (METex14) skipping occurs in 3–4% of non-small-cell lung cancer (NSCLC) cases. Low frequency of this alteration necessitated open-label, single-arm trials to investigate MET inhibitors. Since broad MET biomarker testing was only recently introduced in many countries, there is a la...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael Thomas, Petros Christopoulos, Wade T Iams, Julien Mazieres, Alexis B Cortot, Nir Peled, Gabriele Minuti, Egbert F Smit, Francois Audhuy, Karin Berghoff, S Peter Eggleton, Frank Fries, Maike Hildenbrand, Peter Liu, Seyed Hamidreza Mahmoudpour, Christoph Menzel, Dina Oksen
Format: Article
Language:English
Published: Becaris Publishing Limited 2025-01-01
Series:Journal of Comparative Effectiveness Research
Subjects:
cancer registry
metex14 skipping
nsclc
real-world data
targeted therapy
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items